v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating expenses        
Research and development expenses $ 32,419 $ 28,642 $ 96,191 $ 71,992
Selling, general and administrative expenses 8,411 5,035 20,287 17,822
Total operating expenses 40,830 33,677 116,479 89,814
Operating loss (40,830) (33,677) (116,479) (89,814)
Gain/(loss) from the change in fair value of derivative liabilities 3,990 (854) 12,398 (9,833)
Financial investment income 3,629 2,802 7,961 9,039
Related party loan interest income 430 1,158 2,875 3,149
Interest expense (835) (31) (1,861) (31)
Other (loss)/gain, net (1,744) 489 (921) 672
Loss before income taxes (35,361) (30,112) (96,027) (86,817)
Income tax expense 427 1,098 1,445 1,574
Net loss $ (35,787) $ (31,210) $ (97,472) $ (88,392)
Weighted-average number of shares outstanding – basic (in shares) 297,833 275,887 283,484 275,671
Weighted-average number of shares outstanding – diluted (in shares) 297,833 275,887 283,484 275,671
Net loss per share basic (in dollars per share) $ (0.12) $ (0.11) $ (0.34) $ (0.32)
Net loss per share diluted (in dollars per share) $ (0.12) $ (0.11) $ (0.34) $ (0.32)

Source